|
1.
|
Tsukagoshi S, Hashimoto Y, Fujii G,
Kobayashi H, Nomoto K and Orita K: Krestin (PSK). Cancer Treat Rev.
11:131–155. 1984. View Article : Google Scholar
|
|
2.
|
Torisu M, Hayashi Y, Ishimitsu T, Fujimura
T, Iwasaki K, Katano M, Yamamoto H, Kimura Y, Takesue M, Kondo M
and Nomoto K: Significant prolongation of disease-free period
gained by oral polysaccharide K (PSK) administration after curative
surgical operation of colorectal cancer. Cancer Immunol Immunother.
31:261–268. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Yoshitani S and Takashima S: Efficacy of
postoperative UFT (Tegafur/Uracil) plus PSK therapies in elderly
patients with resected colorectal cancer. Cancer Biother
Radiopharm. 24:35–40. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Ohwada S, Ikeya T, Yokomori T, Kusaba T,
Roppongi T, Takahashi T, Nakamura S, Kakinuma S, Iwazaki S,
Ishikawa H, et al: Adjuvant immunochemotherapy with oral
Tegafur/Uracil plus PSK in patients with stage II or III colorectal
cancer: a randomized controlled study. Br J Cancer. 90:1003–1010.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Araya S, Nio Y, Hayashi H, Masai Y,
Tsubono M, Ishigami S and Imamura M: Various plant-derived
polysaccharides augment the expression of HLA on Colo205 human
colonic cancer line. J Jpn Soc Cancer Ther. 29:1965–1973. 1994.(In
Japanese).
|
|
6.
|
Hirose K, Zachariae CO, Oppenheim JJ and
Matsushima K: Induction of gene expression and production of
immunomodulating cytokines by PSK in human peripheral blood
mononuclear cells. Lymphokine Res. 9:475–483. 1990.PubMed/NCBI
|
|
7.
|
Algarra I, Collado A, Garcia Lora A and
Garrido F: Differential effect of protein-bound polysaccharide
(PSK) on survival of experimental murine tumors. J Exp Clin Cancer
Res. 18:39–46. 1999.PubMed/NCBI
|
|
8.
|
Harada M, Matsunaga K, Oguchi Y, Iijima H,
Tamada K, Abe K, Takenoyama M, Ito O, Kimura G and Nomoto K: Oral
administration of PSK can improve the impaired anti-tumor
CD4+ T-cell response in gut-associated lymphoid tissue
(GALT) of specific-pathogen-free mice. Int J Cancer. 70:362–372.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Fidler IJ and Ellis LM: The implications
of angiogenesis for the biology and therapy of cancer metastasis.
Cell. 79:185–188. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Hanahan D and Folkman J: Patterns and
emerging mechanisms of the angiogenic switch during tumorigenesis.
Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Stoeltzing O, Liu W, Reinmuth N, Parikh A,
Ahmad SA, Jung YD, Fan F and Ellis LM: Angiogenesis and
antiangiogenic therapy of colon cancer liver metastasis. Ann Surg
Oncol. 10:722–733. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Ishigami SI, Arii S, Furutani M, Niwano M,
Harada T, Mizumoto M, Mori A, Onodera H and Imamura M: Predictive
value of vascular endothelial growth factor (VEGF) in metastasis
and prognosis of human colorectal cancer. Br J Cancer.
78:1379–1384. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Tokunaga T, Oshika Y, Abe Y, Ozeki Y,
Sadahiro S, Kijima H, Tsuchida T, Yamazaki H, Ueyama Y, Tamaoki N
and Nakamura M: Vascular endothelial growth factor (VEGF) mRNA
isoform expression pattern is correlated with liver metastasis and
poor prognosis in colon cancer. Br J Cancer. 78:998–1002. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Goi T, Yamaguchi A, Nakagawara G, Urano T,
Shiku H and Furukawa K: Reduced expression of deleted colorectal
carcinoma (DCC) protein in established colon cancers. Br J Cancer.
77:466–471. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Fujishima Y, Goi T, Kimura Y, Hirono Y,
Katayama K and Yamaguchi A: MUC2 protein expression status is
useful in assessing the effects of hyperthermic intraperitoneal
chemotherapy for peritoneal dissemination of colon cancer. Int J
Oncol. 40:960–964. 2012.
|
|
16.
|
Goi T, Fujioka M, Satoh Y, Tabata S,
Koneri K, Nagano N, Hirono Y, Katayama K, Hirose K and Yamaguchi A:
Angiogenesis and tumor proliferation/metastasis of human colorectal
cancer cell line SW620 transfected with endocrine
glands-derived-vascular endothelial growth factor, as a new
angiogenic factor. Cancer Res. 64:1906–1910. 2004. View Article : Google Scholar
|
|
17.
|
Nagano H, Goi T, Koneri K, Hirono Y,
Katayama K and Yamaguchi A: Endocrine gland-derived vascular
endothelial growth factor (EG-VEGF) expression in colorectal
cancer. J Surg Oncol. 96:605–610. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Semenza GL: Oxygen homeostasis. Wiley
Interdiscip Rev Syst Biol Med. 2:336–361. 2010. View Article : Google Scholar
|
|
19.
|
Semenza GL: HIF-1 inhibitors for cancer
therapy: from gene expression to drug discovery. Curr Pharm Des.
15:3839–3943. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Liao D and Johnson RS: Hypoxia: a key
regulator of angiogenesis in cancer. Cancer Metastasis Rev.
26:281–290. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Chan DA and Giaccia AJ: Hypoxia, gene
expression, and metastasis. Cancer Metastasis Rev. 26:333–339.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Zhou J, Schmid T, Schnitzer S and Brüne B:
Tumor hypoxia and cancer progression. Cancer Lett. 237:10–21. 2006.
View Article : Google Scholar
|
|
23.
|
Harris AL: Hypoxia – a key regulatory
factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002.
|
|
24.
|
Schmid T, Zhou J, Köhl R and Brüne B: p300
relieves p53-evoked transcriptional repression of hypoxia-inducible
factor-1 (HIF-1). Biochem J. 380:289–295. 2004. View Article : Google Scholar : PubMed/NCBI
|
